mProX™ Human THRA Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Nuclear Receptor
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
Joseph
Verified Customer
Michelle
Verified Customer
Any questions about our products? Please visit our frequently asked questions page.
Published Data
Fig.1 T3 represses STMN1 expression in HepG2 cell lines
THR protein expression levels in THR overexpressing and control HepG2 cell lines. HepG2-THRA, HepG2-THRB, and HepG2-Neo cell lysates immunoblots.
Ref: Tseng, Yi-Hsin, et al. "Thyroid hormone suppresses expression of stathmin and associated tumor growth in hepatocellular carcinoma." Scientific reports 6.1 (2016): 38756.
Pubmed: 27934948
DOI: 10.1038/srep38756
Research Highlights
THRA mutations might be more prevalent than thought. A molecular analysis of THRA abnormalities is strongly advised in patients exhibiting clinical signs of mild hypothyreosis without evidence of the condition being confirmed by endocrine studies.
Tylki-Szymańska, Anna, et al. "Thyroid hormone resistance syndrome due to mutations in the thyroid hormone receptor α gene (THRA)." Journal of medical genetics 52.5 (2015): 312-316.
Pubmed:
25670821
DOI:
10.1136/jmedgenet-2014-102936
This example demonstrates that even if clinical and biological aspects are different from previously reported cases of RTHα, patients with a low FT4/FT3 ratio should be examined for THRA mutations.
Espiard, Stéphanie, et al. "A novel mutation in THRA gene associated with an atypical phenotype of resistance to thyroid hormone." The Journal of Clinical Endocrinology & Metabolism 100.8 (2015): 2841-2848.
Pubmed:
26037512
DOI:
10.1210/jc.2015-1120
